TargetCytochrome P450 2C9(Homo sapiens (Human))
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4.10E+3nMT: 2°CAssay Description:Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation o...More data for this Ligand-Target Pair
TargetCytochrome P450 2C9(Homo sapiens (Human))
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4.90E+3nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
TargetCytochrome P450 2C9(Homo sapiens (Human))
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
US Patent
Affinity DataIC50: 4.90E+3nMAssay Description:The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).More data for this Ligand-Target Pair